These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24969622)

  • 1. Emergency reversal of anticoagulation: novel agents.
    Levine M; Goldstein JN
    Curr Neurol Neurosci Rep; 2014 Aug; 14(8):471. PubMed ID: 24969622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.
    Peacock WF
    Hosp Pract (1995); 2014 Oct; 42(4):75-82. PubMed ID: 25502131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of target-specific oral anticoagulants.
    Siegal DM; Cuker A
    Drug Discov Today; 2014 Sep; 19(9):1465-70. PubMed ID: 24880102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monitoring options and reversal agents for oral anticoagulants].
    Thorup SB; Husted SE; Vang ML
    Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
    Cuker A; Siegal DM; Crowther MA; Garcia DA
    J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory monitoring of the non-vitamin K oral anticoagulants.
    Blann AD; Lip GY
    J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
    [No Abstract]   [Full Text] [Related]  

  • 8. Newer clinically available antithrombotics and their antidotes.
    Lévy S
    J Interv Card Electrophysiol; 2014 Sep; 40(3):269-75. PubMed ID: 24934756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
    Enriquez A; Lip GY; Baranchuk A
    Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.
    Ment J
    Vasc Health Risk Manag; 2015; 11():317-32. PubMed ID: 26089678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants.
    Meijers JCM; Bakhtiari K; Zwiers A; Peters SLM
    Thromb Res; 2023 Jul; 227():17-24. PubMed ID: 37207560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
    Scaglione F
    Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician.
    Lohrmann GM; Atwal D; Augoustides JG; Askar W; Patel PA; Ghadimi K; Makar G; Gutsche JT; Shamoun FE; Ramakrishna H
    J Cardiothorac Vasc Anesth; 2016 Jun; 30(3):823-30. PubMed ID: 27080265
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment with oral anticoagulants in older patients: Should warfarin still be prescribed?].
    Lafuente-Lafuente C; Oasi C; Belmin J
    Presse Med; 2019 Feb; 48(2):154-164. PubMed ID: 30528147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.
    Miyares MA; Davis K
    Am J Health Syst Pharm; 2012 Sep; 69(17):1473-84. PubMed ID: 22899742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
    Steed MB; Swanson MT
    Oral Maxillofac Surg Clin North Am; 2016 Nov; 28(4):515-521. PubMed ID: 27624772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).
    Werth S; Breslin T; NiAinle F; Beyer-Westendorf J
    Am J Cardiovasc Drugs; 2015 Aug; 15(4):235-42. PubMed ID: 25940651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.